Arcturus Therapeutics Holdings Inc (ARCT)
17.06
+0.90
(+5.53%)
USD |
NASDAQ |
Nov 21, 16:00
17.03
-0.04
(-0.21%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Revenue (Quarterly): 38.82M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 38.82M |
| June 30, 2024 | 45.98M |
| March 31, 2024 | 32.60M |
| December 31, 2023 | 25.08M |
| September 30, 2023 | 43.38M |
| June 30, 2023 | 9.565M |
| March 31, 2023 | 79.73M |
| December 31, 2022 | 160.05M |
| September 30, 2022 | 13.37M |
| June 30, 2022 | 27.09M |
| March 31, 2022 | 5.244M |
| December 31, 2021 | 5.794M |
| September 30, 2021 | 2.437M |
| June 30, 2021 | 2.001M |
| March 31, 2021 | 2.127M |
| December 31, 2020 | 2.238M |
| September 30, 2020 | 2.333M |
| June 30, 2020 | 2.322M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.646M |
| December 31, 2019 | 2.968M |
| September 30, 2019 | 3.318M |
| June 30, 2019 | 10.15M |
| March 31, 2019 | 4.35M |
| December 31, 2018 | 7.577M |
| September 30, 2018 | 3.423M |
| June 30, 2018 | 2.386M |
| March 31, 2018 | 2.367M |
| December 31, 2017 | 2.02M |
| September 30, 2017 | 3.296M |
| June 30, 2017 | 3.761M |
| March 31, 2017 | |
| December 31, 2016 | 20.38M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 6.138M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.001M
Minimum
Jun 2021
160.05M
Maximum
Dec 2022
25.29M
Average
7.680M
Median
Revenue (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | -- |
| Bioventus Inc | 138.96M |
| Liquidia Corp | 4.448M |
| Pfizer Inc | 17.70B |
| AIM ImmunoTech Inc | 0.035M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.903M |
| Total Expenses (Quarterly) | 49.55M |
| EPS Diluted (Quarterly) | -0.26 |
| Enterprise Value | 200.83M |
| Profit Margin (Quarterly) | -17.78% |
| Earnings Yield | -13.01% |
| Normalized Earnings Yield | -12.86 |